Literature DB >> 9767365

Investigation into thiol conjugation of transthyretin in hereditary transthyretin amyloidosis.

O B Suhr1, Y Ando, P I Ohlsson, A Olofsson, K Andersson, E Lundgren, M Ando, G Holmgren.   

Abstract

BACKGROUND: For all forms of amyloidosis, the amyloid-generating mechanism is unknown. Familial amyloidotic polyneuropathy type I is caused by a variant transthyretin (TTR Met-30). As electrospray ionization mass spectrometry (ESI-MS) discloses both thiol-conjugated and -unconjugated forms of wild-type and variant TTR, we wanted to investigate the relationship between TTR conjugation and clinically overt amyloid disease.
METHODS: Plasma from 35 individuals (12 symptomatic TTR Met-30 carriers, nine asymptomatic and 14 healthy control subjects) were analysed using ESI-MS.
RESULTS: The total TTR concentration was significantly lower in symptomatic TTR Met-30 carriers than in control subjects. An increased percentage of conjugated TTR Met-30 was found in symptomatic carriers compared with asymptomatic, whereas the percentage conjugated wild-type TTR was similar for control subjects, asymptomatic and symptomatic TTR Met-30 carriers.
CONCLUSION: The finding of a decreased ratio of unconjugated to conjugated TTR Met-30 in plasma samples from symptomatic TTR Met-30 carriers indicates that thiol conjugation of TTR could be involved in amyloid formation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9767365     DOI: 10.1046/j.1365-2362.1998.00345.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  6 in total

1.  Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma.

Authors:  H E Purkey; M I Dorrell; J W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-08       Impact factor: 11.205

2.  Decreased clearance of serum retinol-binding protein and elevated levels of transthyretin in insulin-resistant ob/ob mice.

Authors:  Nimesh Mody; Timothy E Graham; Yuki Tsuji; Qin Yang; Barbara B Kahn
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-02-19       Impact factor: 4.310

3.  A possible role for miRNA silencing in disease phenotype variation in Swedish transthyretin V30M carriers.

Authors:  Malin Olsson; Nina Norgren; Konen Obayashi; Violaine Plante-Bordeneuve; Ole B Suhr; Kristina Cederquist; Jenni Jonasson
Journal:  BMC Med Genet       Date:  2010-09-14       Impact factor: 2.103

4.  Identification of S-sulfonation and S-thiolation of a novel transthyretin Phe33Cys variant from a patient diagnosed with familial transthyretin amyloidosis.

Authors:  Amareth Lim; Tatiana Prokaeva; Mark E McComb; Lawreen H Connors; Martha Skinner; Catherine E Costello
Journal:  Protein Sci       Date:  2003-08       Impact factor: 6.725

5.  Urinary Transthyretin as a Biomarker in ATTRv Val50Met Amyloidosis.

Authors:  Hiroaki Matsushita; Yohei Misumi; Teruaki Masuda; Masamitsu Okada; Fumika Inoue; Mitsuharu Ueda; Yukio Ando
Journal:  Pathophysiology       Date:  2022-06-29

6.  Allele specific expression of the transthyretin gene in swedish patients with hereditary transthyretin amyloidosis (ATTR V30M) is similar between the two alleles.

Authors:  Nina Norgren; Urban Hellman; Bo Göran Ericzon; Malin Olsson; Ole B Suhr
Journal:  PLoS One       Date:  2012-11-19       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.